Articles tagged with: SLAMF7 Targeted Therapies

News»

[ by | Jun 25, 2015 3:02 pm | 6 Comments ]
Multiple Myeloma Highlights From The 2015 ASCO, EHA, And IMWG Annual Summit Meetings

The annual meetings of the American Society of Clinical Oncology (ASCO) and the Euro­pean He­ma­tol­ogy Asso­ci­a­tion (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral pre­sen­ta­tions, posters, and e-abstracts summarizing the re­­sults of new on­col­ogy- and he­ma­tol­ogy-related re­search.

Included in the re­search pre­sented at the two meetings were more than 200 stud­ies discussing new mul­ti­ple myeloma-related findings.

In addi­tion to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Work­ing Group (IMWG) …

Read the full story »

News»

[ by | Jun 7, 2015 1:15 pm | Comments Off ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Potential New Myeloma Therapies

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a num­ber of poster pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, re­search re­­sults are made avail­able for review by meeting attendees in the form of posters, each of which summarizes the re­­sults of a single study. Each poster is typ­i­cally about two feet high by three or four feet in length, and all posters during a ses­sion are dis­played throughout a large conference hall.

Most of the myeloma-related …

Read the full story »

News»

[ by | May 29, 2015 11:52 pm | 2 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2015)

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier to­day, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and re­searchers from all over the world are ex­pec­ted to attend the five-day meeting to discuss cur­rent re­search in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused spe­cif­i­cally on mul­ti­ple myeloma. In fact, more than 90 myeloma-related stud­ies are scheduled to be pre­sented, in one form or another, in con­nec­tion with the …

Read the full story »

News, Opinion»

[ by | Jan 30, 2015 3:07 pm | 4 Comments ]
The Myeloma Quiz – January 2015

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a hap­pen­ing time for the mul­ti­ple myeloma com­munity. The short span of time witnessed the pub­li­ca­tion of up­dated criteria for the diag­nosis of mul­ti­ple myeloma from the Inter­na­tional Myeloma Work­ing Group (IMWG). In addi­tion, the 56th annual meeting of the American Society of He­ma­tol­ogy (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster pre­sen­ta­tions.

Therefore, it is again …

Read the full story »

News»

[ by | Dec 8, 2014 7:02 am | 5 Comments ]
ASH 2014 Multiple Myeloma Update – Day One: Poster Session

Saturday was the official first day of the 2014 American Society of Hema­tology (ASH) annual meeting. The day featured a wide range of in­ter­est­ing pre­sen­ta­tions about mul­ti­ple myeloma.

Oral pre­sen­ta­tions about new treat­ments under devel­op­ment were given mid-day and were summarized in a Beacon ASH Daily Update published yes­ter­day morn­ing.

During Saturday evening, a poster session took place where im­por­tant new re­search findings were summarized in posters dis­played throughout two separate large conference halls.

The stud­ies covered a variety of myeloma-related topics, ranging from new treat­ments being devel­oped for myeloma, com­bi­na­tion ther­a­pies …

Read the full story »

News»

[ by | Dec 5, 2014 7:41 am | 4 Comments ]
ASH 2014 Preview: New Multiple Myeloma Treatments On The Horizon

The 2014 annual meeting of the American Society of He­ma­tol­ogy (ASH) starts tomorrow, De­cem­ber 5, in San Francisco, and will con­tinue until next Tuesday.

The ASH annual meeting is one of sev­er­al large med­i­cal conferences where myeloma-related re­search findings are pre­sented each year.  However, from a mul­ti­ple myeloma perspective, the ASH meeting is generally the most im­por­tant of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The pre­sen­ta­tions will summarize cur­rent re­search on a wide range of topics, in­clud­ing the biology of the dis­ease …

Read the full story »

Press Releases»

[ by | Oct 1, 2014 10:00 am | Comments Off ]
  • This Phase I trial will test the safety and tolerability of lirilumab (BMS-986015) in combination with elotuzumab (BMS-901608) in patients with multiple myeloma
  • This new Phase I initiated by Bristol-Myers Squibb is the first combination trial of lirilumab in a hematological tumor type

Marseille, France (Press Release) - Innate Pharma SA (the "company" -  euronext paris:FR0010331421 - IPH), the innate immunity com­pany devel­op­ing first-in-class thera­peutic anti­bodies for cancer and in­flam­ma­tory dis­eases, to­day an­nounced that a new Phase I com­bi­na­tion trial with lirilumab, a …

Read the full story »